This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay D is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
As one of BrainsWay’s founders, Yiftach Roth has served as the company’s Research and Development Manager since May 2006 and as a member of the Board of Directors since November 2006.
From 2003 through 2006, Dr. Roth worked in the Advanced Technology Center of the Chaim Sheba Medical Center at Tel Hashomer as a researcher in the field of Magnetic Resonance Imaging (MRI).
His primary research interests are TMS and Magnetic Resonance Imaging (MRI), and he was one of the two key inventors of our patented Deep TMS coil.
Dr. Roth holds B.Sc. and M.Sc. degrees in Physics and a Ph.D. in Medical Physics from Tel Aviv University.